KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$595.0 million.

  • Teva Pharmaceutical Industries' Deferred Taxes fell 195937.5% to -$595.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$671.0 million, marking a year-over-year decrease of 583.6%. This contributed to the annual value of -$671.0 million for FY2025, which is 583.6% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Deferred Taxes stood at -$595.0 million for Q4 2025, which was down 195937.5% from $107.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Deferred Taxes' 5-year high stood at $150.0 million during Q4 2022, with a 5-year trough of -$1.1 billion in Q2 2022.
  • For the 5-year period, Teva Pharmaceutical Industries' Deferred Taxes averaged around -$140.3 million, with its median value being -$48.5 million (2023).
  • The largest annual percentage gain for Teva Pharmaceutical Industries' Deferred Taxes in the last 5 years was 45000.0% (2022), contrasted with its biggest fall of 686875.0% (2022).
  • Over the past 5 years, Teva Pharmaceutical Industries' Deferred Taxes (Quarter) stood at -$133.0 million in 2021, then surged by 212.78% to $150.0 million in 2022, then crashed by 78.67% to $32.0 million in 2023, then changed by 0.0% to $32.0 million in 2024, then crashed by 1959.38% to -$595.0 million in 2025.
  • Its Deferred Taxes stands at -$595.0 million for Q4 2025, versus $107.0 million for Q3 2025 and -$211.0 million for Q2 2025.